[1] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015,65(1): 5-29. [2] 韩苏军,张思维,陈万青,等. 中国前列腺癌发病现状和流行趋势分析[J]. 临床肿瘤学杂志, 2013,18(4): 330-334. [3] NCCN. The NCCN prostate cancer clinical practice guidelines in oncology (version 2.2016)[EB/OL]. Fort Washington: NCCN,2016[2016-03-13]. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pd [4] Stephenson A J, Scardino P T, Eastham J A, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy[J]. J Am Soc Clin Oncol, 2005, 23(28): 715-717. [5] Swindle P, Eastham J M, Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens[J]. J Urol, 2005, 179(Suppl 5): 47-51. [6] Kupelian P A, Katcher J, Levin H S, et al. State T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy?[J]. Int J Radiat Oncol Biol Phy, 1997,37(5): 1043-1052. [7] Mottet N, Bellmunt J, Bolla M, et al. European agyssociation of Urology Guidelines-2015[U]. European Association Urology, 2015: 25-27. [8] Thompson I M, Valicenti R K, Albertsen P, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline[J]. J Urol, 2013,190(2): 441-449. [9] 那彦群,叶章群, 中国泌尿外科疾病诊断治疗指南手册[M]. 北京:人民卫生出版社,2014: 61-89. [10] Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)[J]. Lancet, 2012, 380(9858): 2018-2027. [11] Thompson I M, Tangen C M, Jorge P, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial[J]. JAMA, 2006, 296(19): 2329-2335. [12] Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95[J]. J Clin Oncol, 2009, 27(18): 2924-2930. [13] van der Poel H G, Tillier C, de Blok W, et al. Salvage radiotherapy after robot-assisted laparoscopic radical prostatectomy[J]. Urology, 2013, 82(4): 834-839. [14] Ohri N, Dicker A P, Trabulsi E J, et al. Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling[J]. Eur J Cancer, 2012, 48(6): 837-844. [15] Geinitz H, Riegel M G, Thamm R, et al. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy[J]. Int J Radiat Oncol Biol Phys, 2012,82(5): 1930-1937. [16] Siegmann A, Bottke D, Faehndrich J, et al. Salvage radiotherapy after prostatectomy What is the best time to treat?[J]. Radiothe Oncol, 2012, 103(2): 239-243. [17] Choo R, Danjoux C, Gardner S, et al. Efficacy of salvage radiotherapy plus 2-Year androgen suppression for postradical prostatectomy patients with PSA relapse[J]. Int J Radiat Oncol Biol Phys, 2009, 75(4): 983-989. [18] Pasquier D, Ballereau C. Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review[J]. Int J Radiat Oncol Biol Phys, 2008, 72(4): 972-979. [19] Bolla M, Poppel H V, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)[J]. Lancet, 2005, 366(9485): 572-578. [20] Thompson I M, Tangen C M, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-Term followup of a randomized clinical trial[J]. J Urol, 2009, 181(3): 956-962. [21] Dorff T B, Flaig T W, Tangen C M, et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 Study[J]. J Clin Oncol, 2011, 29(15): 2040-2045. |